Improving haematopoietic stem cell transplantation outcome
Research type
Research Study
Full title
Improving haematopoeitic stem cell outcome through studies of alloreactivity, immune reconstitution, biomarkers and novel therapies.
IRAS ID
129780
Contact name
Matthew Collin
Contact email
Sponsor organisation
Newcastle upon Tyne Hospitals NHS Foundation Trust
Clinicaltrials.gov Identifier
097941/Z/11/Z, Wellcome Trust Clinical Research Training Fellowship (L Jardine); 101155/Z/13/Z, Wellcome Trust Intermediate Fellowship (V Bigley)
Research summary
Tissue samples derived from recipients of bone marrow transplantation (BMT) and their donors are integral to a continuing translational research programme conducted by Investigators at Newcastle University and the Northern Centre for Bone Marrow Transplantation at the Freeman Hospital.
HSCT is a critical treatment for blood cancers such as leukaemia and lymphoma but remains imperfect with approximately 60% survival at 2 years. Treatment failure is due to toxicity (10-20%) or relapse of disease (20-30%). The outcome of HSCT is determined by immune responses of the donor. Toxicity is either due to infection, through a failure of the donor immune system to reconstitute effectively or graft versus host disease (GVHD), an excessive reaction of the donor to the recipient (also known as 'alloreactivity'). Relapse occurs when there is an inadequate immune response of the donor to malignant cells of the recipient. Opportunistic viral infections e.g. CMV (cytomegalovirus)can also be life threatening.
This continuing research programme is designed to gain a better understanding of human alloreactivity and immune responses and to develop new approaches to improving the outcome of HSCT through better diagnostic tests and new cellular therapies. Profs Collin and Dickinson have led previous research programmes funded by the EU, MRC, Wellcome Trust and Lymphoma and Leukaemia Research. This application will continue the work with new funding providing by EU and Wellcome and further streamline the provision of research samples for several strands of research to minimise inconvenience to participants.
The aims of the study include the development and storage (under Newcastle Bio-manufacturing Facility License 11122- Person Designate Andrew Gennery)of donor anti-viral Tcells and donor mesenchymal stem cells for future potential clinical use on an individual patient basis.
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
14/NE/1136
Date of REC Opinion
25 Nov 2014
REC opinion
Further Information Favourable Opinion